Search Bar & Filters
Found 22 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.
Actively Recruiting
Researchers are evaluating how efgartigimod PH20 SC affects thyroid function in adults with Graves Disease GD. The study aims to assess the safety, tolerance, and immune response to efgartigimod. It also examines how the drug is processed in the body and its impact on antibody levels. This is a Phase 3, randomized, double-masked, placebo-controlled trial involving adult participants with GD not well controlled by antithyroid drugs. The study includes three parts Part A is a double-blind treatment period where participants receive either efgartigimod or placebo via subcutaneous injection using a prefilled syringe. Part B is a treatment or observation period with similar treatments. Part C is an open-label period where all participants receive efgartigimod. Participation in each part depends on the participants response to treatment. Treatment is given by subcutaneous injection, and placebo is used for comparison in earlier parts. Participants will be involved in the study for 63 to 135 weeks depending on their treatment response. Researchers will monitor thyroid hormone levels, antibody presence, immune system activity, and drug concentration in the blood. Safety and side effects will be tracked throughout. Various questionnaires and lab tests will be used to assess thyroid function and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs at 24 weeks in Part A.
Actively Recruiting
Researchers are evaluating the effectiveness of two different doses of the drug AP-472 as an add-on treatment to levodopa in people with Parkinsons disease who experience motor fluctuations. This Phase 2 study aims to compare these doses with a placebo over a 14-week period to better understand how AP-472 affects motor symptoms when combined with standard levodopa therapy. Participants will be randomly assigned to receive either 100 mg or 300 mg of AP-472 daily, or a placebo, without knowing which treatment they are receiving. The study includes a screening phase, a 4-week period with stable Parkinsons medications, and a 12-week treatment phase during which some adjustments to levodopa dosing are allowed if necessary. During their participation, individuals will be closely monitored with assessments including motor diaries to track daily OFF time, various Parkinsons disease rating scales, and sleepiness questionnaires. The primary focus is on changes in average daily OFF time after 12 weeks of treatment. Safety and effectiveness will be evaluated throughout, with the entire study lasting about 14 weeks from start to finish.
Actively Recruiting
Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of various drug regimens for people with myasthenia gravis, a condition that affects muscle strength. This platform study uses a master protocol allowing multiple treatments to be tested separately but under a common framework. The goal is to find treatments that reduce side effects and improve quality of life. Participants may receive treatments including intravenous infusions of efgartigimod, empasiprubart, or placebo, as well as subcutaneous injections of efgartigimod PH20 using a pre-filled syringe. The study includes different treatment groups based on specific myasthenia gravis subtypes and prior responses to therapy. Each treatment period varies in length depending on the specific intervention appendix. Throughout the study, participants undergo screening, treatment, and follow-up periods lasting up to approximately seven years depending on the treatment group. Researchers will monitor safety and tolerability as the primary outcomes, along with evaluating how well the treatments work. Participants will have regular assessments and safety monitoring throughout their involvement in the platform study.
Actively Recruiting
Researchers are evaluating the safety and therapeutic relevance of empasiprubart as an add-on treatment to efgartigimod in people with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis who have only partially responded to efgartigimod. This Phase 2a exploratory study is part of the larger ADAPT Forward platform, aiming to find safer and more effective treatment approaches to reduce side effects and improve quality of life for patients with myasthenia gravis. Participants first enter a run-in period where they receive intravenous efgartigimod. Those eligible then move to the add-on period, receiving both efgartigimod and empasiprubart intravenously. Participants not eligible for the add-on phase continue with efgartigimod alone during the safety follow-up period. The entire study duration for each participant lasts up to about 54 weeks. Throughout the study, participants are closely monitored with assessments including adverse event tracking, muscle strength and function evaluations, and quality of life questionnaires. The primary outcome is the incidence of adverse events during the first 21 weeks, with secondary measures examining changes in clinical scores such as MG-ADL and QMG. Safety follow-up continues for those not in the add-on phase to ensure ongoing monitoring of treatment effects.
Actively Recruiting
Researchers are investigating the safety and effectiveness of empasiprubart intravenous monotherapy in adults with acetylcholine receptor antibody AChR-Ab seropositive generalized myasthenia gravis gMG. This study is part of the broader ADAPT Forward platform, which aims to identify the best treatments that reduce side effects and improve quality of life for people with myasthenia gravis. The research is conducted under a phase 2a randomized, double-blinded, placebo-controlled trial design. Participants who qualify will be randomly assigned to receive either empasiprubart IV or a placebo during the double-blinded treatment period lasting up to 12 weeks. After this phase, all participants will receive open-label efgartigimod PH20 administered subcutaneously via pre-filled syringe during a safety follow-up period. The total study duration for each participant is approximately 45 weeks. Throughout the trial, participants will undergo various assessments including monitoring for adverse events, evaluation of myasthenia gravis activities of daily living MG-ADL scores, and quantitative myasthenia gravis QMG scores up to week 12. The study will track changes in these scores and the proportion of participants reaching meaningful clinical improvements. Safety and tolerability will be closely observed during treatment and follow-up periods to understand the effects of the study drugs.
Actively Recruiting
Researchers are evaluating tanruprubart, also known as ANX005, in people aged 8 to 85 years with Guillain-Barre Syndrome GBS. This phase 3 open-label study aims to understand how tanruprubart behaves in the body, its effects on the immune system, early signs of its impact on GBS, and its safety profile across adult and pediatric participants in the United States, Canada, and Europe. Participants will receive a single intravenous infusion of tanruprubart at a dose of 30 mg per kilogram on the first day of the study. This single-dose treatment is designed to assess the pharmacokinetics and pharmacodynamics of the drug, along with early efficacy signals and safety data during the initial 15 days following infusion. During the study, participants will be monitored through blood tests measuring tanruprubart concentration and complement protein levels, as well as clinical assessments such as the Medical Research Council Sumscore to evaluate muscle strength changes. Researchers will focus on drug concentration over time and the time to reach maximum serum concentration. The primary measurement period extends up to day 15, with safety and efficacy monitored closely throughout this timeframe.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a multi-ingredient protein formula in healthy adults aged 21 to 65 years with a body mass index between 18.5 and 34.9 kgm. The study is an open-label, two-arm pilot trial that aims to assess the tolerability, consumer acceptability, and effects on well-being of two flavors Vanilla Protein Formula and Chocolate Protein Formula. This research is important to understand the real-world use of this specific combination of protein ingredients before larger trials. Participants will be assigned to receive either the vanilla or chocolate flavored protein formula, consuming one 51-gram scoop daily for 15 consecutive days mixed with water or a beverage of choice. The formulas include fermented yeast protein, bovine collagen peptides, creatine monohydrate, and a prebiotic fiber blend, with slight differences in sweeteners and flavoring. The study is fully remote with no in-person visits or lab tests, using electronic questionnaires to collect data at baseline, Day 7, Day 15, and a follow-up 4 to 7 days after finishing. During the study, participants will report their experience with safety and tolerability, global health status using the Global-10 scale, and cognitive function with PROMIS tools. Consumer liking of the product will be measured by a 9-point hedonic scale. Adherence and any adverse events will be tracked via brief check-ins on Days 1, 3, 7, and 15. The entire involvement is based on self-reporting completed electronically from home.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a study to compare bone mineral density BMD measurements from two types of low-dose X-ray exams EOSedge and traditional DXA. The study aims to determine if the T-scores calculated from these two imaging methods agree. This multi-center, prospective, controlled, cross-sectional agreement study involves participants who either need EOSedge imaging as part of their routine care or volunteers undergoing non-diagnostic imaging. Participants will undergo both EOSedge and DXA scans. EOSedge exams will be performed as usual for evaluating spinal or orthopedic conditions, while DXA exams will be done as study-prescribed or standard care, ideally on the same day as EOSedge but up to 60 days apart. Healthy volunteers will receive both imaging tests, and those receiving EOSedge imaging as standard care will also receive an additional DXA scan. During the study, participants will have demographic and diagnostic information collected via case report forms and complete a questionnaire before the DXA scan. The researchers will assess the agreement of T-scores between the two imaging methods over a period of up to 60 days. The total duration of participation covers consent through completion of image acquisition. Safety is monitored by excluding participants with conditions affecting imaging quality or safety risks.
1-10 of 22
1